Complete remission in a patient with acute myelogenous leukemia treated with leukocyte α-interferon and cimetidine
(1984) In Cancer Immunology Immunotherapy 17(1). p.69-71- Abstract
A 76-year-old woman with acute myelogenous leukemia with approximately 65% myeloblasts on bone marrow examination was treated daily with a combination of 4 megaU of leukocyte interferon IM and 1,000 mg cimetidine PO. During therapy there was a gradual decrease of bone marrow myeloblasts down to 9% and a normalization of peripheral white blood cells. The treatment was discontinued after 6 weeks because of increasing fatigue and anorexia. The general condition improved greatly during the following weeks and the patient entered complete remission, which has continued for 6 months so far. In the course of therapy there was a gradual appearance of antibodies showing a selective binding capacity to autochthonous leukemic cells with no... (More)
A 76-year-old woman with acute myelogenous leukemia with approximately 65% myeloblasts on bone marrow examination was treated daily with a combination of 4 megaU of leukocyte interferon IM and 1,000 mg cimetidine PO. During therapy there was a gradual decrease of bone marrow myeloblasts down to 9% and a normalization of peripheral white blood cells. The treatment was discontinued after 6 weeks because of increasing fatigue and anorexia. The general condition improved greatly during the following weeks and the patient entered complete remission, which has continued for 6 months so far. In the course of therapy there was a gradual appearance of antibodies showing a selective binding capacity to autochthonous leukemic cells with no tendency to increased binding to remission cells. The aim of this report is to stimulate a further evaluation of this form of therapy in additional AML patients whenever this might be justified as an alternative to conventional chemotherapy.
(Less)
- author
- Ankerst, Jaro LU ; Fäldt, Roger LU ; Nilsson, P. G. LU ; Flodgren, Per LU and Sjögren, H. O. LU
- organization
- publishing date
- 1984
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Cancer Immunology Immunotherapy
- volume
- 17
- issue
- 1
- pages
- 69 - 71
- publisher
- Springer
- external identifiers
-
- pmid:6587932
- scopus:0021276520
- ISSN
- 0340-7004
- DOI
- 10.1007/BF00205501
- language
- English
- LU publication?
- yes
- id
- 1b90d91a-8b19-427b-94c2-84b8044e9ebc
- date added to LUP
- 2021-01-18 16:36:32
- date last changed
- 2024-01-03 05:23:03
@article{1b90d91a-8b19-427b-94c2-84b8044e9ebc, abstract = {{<p>A 76-year-old woman with acute myelogenous leukemia with approximately 65% myeloblasts on bone marrow examination was treated daily with a combination of 4 megaU of leukocyte interferon IM and 1,000 mg cimetidine PO. During therapy there was a gradual decrease of bone marrow myeloblasts down to 9% and a normalization of peripheral white blood cells. The treatment was discontinued after 6 weeks because of increasing fatigue and anorexia. The general condition improved greatly during the following weeks and the patient entered complete remission, which has continued for 6 months so far. In the course of therapy there was a gradual appearance of antibodies showing a selective binding capacity to autochthonous leukemic cells with no tendency to increased binding to remission cells. The aim of this report is to stimulate a further evaluation of this form of therapy in additional AML patients whenever this might be justified as an alternative to conventional chemotherapy.</p>}}, author = {{Ankerst, Jaro and Fäldt, Roger and Nilsson, P. G. and Flodgren, Per and Sjögren, H. O.}}, issn = {{0340-7004}}, language = {{eng}}, number = {{1}}, pages = {{69--71}}, publisher = {{Springer}}, series = {{Cancer Immunology Immunotherapy}}, title = {{Complete remission in a patient with acute myelogenous leukemia treated with leukocyte α-interferon and cimetidine}}, url = {{http://dx.doi.org/10.1007/BF00205501}}, doi = {{10.1007/BF00205501}}, volume = {{17}}, year = {{1984}}, }